About JUNTEN BIO
JUNTEN BIO is a company based in Chiyoda (Japan) founded in 2018. JUNTEN BIO operates in a competitive market with competitors including KaloCyte, Satellite Bio, CorNeat Vision, Ochre Bio and Stratatech Corp, among others.
- Headquarter Chiyoda, Japan
- SectorsHealthcare
- Website juntenbio.co.jp
- Investors
Funding Insights of JUNTEN BIO
- Total Rounds 2
- Investors Count 1
All 2 funding rounds of JUNTEN BIO with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | – | Debt – Conventional | – | – | |
| Jun 2019 | $1.85M | Seed | – | – | Fujifilm |
1 investors in total: 1 institutional.
Investors in JUNTEN BIO
JUNTEN BIO has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Mizuho Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Commercial banking services are provided internationally from Japan headquarters. | – | mizuhobank.co.jp | Chiyoda City, Japan |
Investor details for JUNTEN BIO
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of JUNTEN BIO
1 people are tracked at JUNTEN BIO (1 in leadership).
| Name | Role | Group |
|---|---|---|
Henan Yacheng | CEO | Leadership |
Complete people profiles for JUNTEN BIO
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of JUNTEN BIO
3 dated milestones of JUNTEN BIO across 5 years, from founding to its latest funding, stage changes and deals.
- Founded JUNTEN BIO is founded.
- Funding First funding round.
- Funding Latest funding round, Debt – Conventional,.
Competitors of JUNTEN BIO
JUNTEN BIO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as KaloCyte, Satellite Bio, CorNeat Vision, Ochre Bio and Stratatech Corp, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kalocyte.com | 2016 | St. Louis, United States | $1.1M | – | Nanotechnology-based red blood cell substitutes are developed. | |
| satellite.bio | 2019 | Cambridge, United States | $110M | 21 | Proprietary implantable satellite organs are developed for cell therapy. | |
| corneat.com | 2015 | – | $4M | – | Nanotechnology-based artificial corneal implants are developed for ophthalmic use. | |
| ochre-bio.com | 2019 | Oxford, United Kingdom | $39.73M | 11 | Genomic medicines for liver diseases are developed using gene therapies. | |
| stratatechcorp.com | 2000 | United States | $3.68M | 47 | Cell-based skin substitutes are developed for therapeutic and research uses. | |
| morphocell.com | 2018 | Montreal, Canada | – | – | Engineered liver tissues are developed for liver disease treatments. | |
| humatrix-medical.com | 2021 | Suzhou, China | – | – | Tissue engineering technologies for cardiovascular regenerative surgeries are developed. | |
| videregen.com | 2012 | Liverpool, United Kingdom | $2.59M | 8 | Tissue repair is advanced through thymus stem cell science by Videregen. | |
| golivertx.com | 2017 | Nantes, France | – | – | Develops stem cell-based therapies to repair liver without transplantation. |
Detailed competitors of JUNTEN BIO
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of JUNTEN BIO
The website of JUNTEN BIO (juntenbio.co.jp) receives about 1.2K visits a month.
- Monthly visits1.2K
▲ 1.1% vs previous month
Websites whose visitors overlap most with JUNTEN BIO. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sysmex-fcm.jp | sysmex-fcm.jp | 100% | – | #5,467,914 | – |
Latest news on Junten Bio
Complete news archive for JUNTEN BIO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to JUNTEN BIO
10 companies that operate in the same segment as JUNTEN BIO (Transplant Medicine), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medical solutions for transplant patients are developed and provided. | 1998 | Brisbane, California, United States | USD 138.21 M | USD 379.81 M | 650 | |
Developer of organ transplantation technology | 1998 | Andover, Massachusetts, United States | USD 265.55 M | USD 605.49 M | 728 | |
Warm storage and transport systems for harvested organs are provided. | 2008 | Oxford, Oxfordshire, United Kingdom | USD 45.42 M | USD 1.36 M | 14 | |
Human tissue-based products are developed for vascular disease applications. | 2004 | Morrisville, United States | USD 424.76 M | USD 2.04 M | 220 | |
Next-generation medicines for CNS and immunological disorders are developed. | 2007 | New York, New York, United States | USD 4.45 M | USD 13.11 M | 81 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Personalized skin tissue therapy is developed by CUTISS for surgeries. | 2017 | Zurich, Switzerland | USD 94.37 M | – | – | |
Game currency trading services are provided by Magenta Piman. | 2016 | Cambridge, Massachusetts, United States | USD 150.5 M | – | 75 | |
T regulatory cell therapies are developed for immunological diseases. | 2019 | London, England, United Kingdom | USD 344.25 M | – | – | |
Therapeutics for transplantation in autoimmune and neurodegenerative diseases are developed. | 2004 | Irvine, California, United States | USD 1.89 M | – | 31 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about JUNTEN BIO
JUNTEN BIO was founded in 2018 and raised its 1st funding round 1 year after it was founded.
JUNTEN BIO is headquartered in Chiyoda, Japan. It is registered at Chiyoda, Tokyo, Japan.
Henan Yacheng is the current CEO of JUNTEN BIO.
Founded in 2018 and based in Chiyoda City, Japan, the company operates in the biotechnology sector, focusing on regenerative medicine. Products such as JB-101, an inducible inhibitory T-cell therapy, are developed to induce immune tolerance in patients undergoing living-donor liver transplants. Operations center on advancing treatments that address transplant-related immune challenges through cellular technologies.
JUNTEN BIO's top competitors include KaloCyte, Ochre Bio and Satellite Bio.
JUNTEN BIO has 1 investor. Key investors include Mizuho Bank.